DSM-Firmenich Sales Exceed €2.3 Billion Amid Perfumery and Beauty Growth
According to reporting by Cosmetics Business, DSM-Firmenich achieved third-quarter sales surpassing €2.3 billion in 2026. This performance was primarily driven by volume-led growth within its perfumery and beauty operations, alongside a significant rise in adjusted EBITDA. The company remains on track to meet its 2026 financial targets as it refocuses its core portfolio.
Context from Industry Pulse
The 2026 performance of DSM-Firmenich highlights a broader trend of beauty-focused conglomerates streamlining operations to drive profitability. By divesting its animal health division for €2.2 billion, the firm is concentrating resources on the high-margin prestige fragrance and beauty ingredient sectors. This strategy mirrors recent movements in the wider industry, such as Kimberly-Clark acquiring Kenvue for $48.7 billion and Puig targeting an €8 billion valuation by 2032. The success of DSM-Firmenich’s consumer fragrance reformulations demonstrates that technical innovation remains a primary driver for sales growth, even as macroeconomic conditions remain volatile across global markets.
Financial results for the third quarter of 2026 show that DSM-Firmenich reached a revenue milestone exceeding €2.3 billion. As Cosmetics Business reports, the company saw its adjusted EBITDA climb by 8 percent on a like-for-like basis, reaching €482 million. This increase from the previous year figure of €458 million was largely attributed to strong demand and volume increases in the beauty and perfumery segments. Management highlighted that consistent innovation within the beauty portfolio helped maintain this momentum despite a challenging global economic climate.
Within the fragrance division, the prestige market proved particularly lucrative. Fine fragrances recorded high single-digit growth, while the consumer fragrance category achieved double-digit gains. Cosmetics Business notes that these consumer-facing successes were bolstered by a combination of new product innovations and successful reformulations. Additionally, the ingredients sector of the business showed steady progress with mid-single-digit growth during the period.
The company is currently undergoing a strategic shift to prioritize nutrition, health, and beauty. This transition included a major announcement earlier in 2026 regarding the divestment of its animal nutrition and health unit. The sale to CVC Capital Partners is estimated at €2.2 billion and represents a significant step in streamlining the organization. This move is designed to enhance the focus on high-growth beauty and wellness sectors where the firm currently sees its strongest win rates.
Looking forward, the firm reports a healthy pipeline of upcoming innovations and high success rates in securing new business. Per Cosmetics Business, the company is also seeing positive results from its internal restructuring and cost-saving initiatives. These efforts are expected to provide a stable foundation for the firm to reach its long-term financial objectives through 2028. Executives expressed confidence that the current business conditions remain supportive of continued margin expansion and top-line growth.
The Industry Pulse Bottom Line
DSM-Firmenich is successfully leveraging volume growth and strategic divestments to sharpen its focus on beauty and health. The 8 percent EBITDA rise suggests that innovation-led reformulations are effectively capturing market share in the prestige and consumer fragrance categories.